$857,637,641
to EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.
ACAM2000, SMALLPOX (VACCINIA) VACCINE, LIVE (ACAM)
Verbatim from USAspending.gov. Capitalization, abbreviations, and codes are unchanged.
What the model surfaced from this award
Latest obligation on a 2019 ACAM2000 smallpox vaccine contract for emergency preparedness supply.
Critical biodefense asset ensuring U.S. population protection against potential smallpox outbreaks or bioterrorism.
Sustains domestic vaccine manufacturing capacity, reducing reliance on foreign suppliers for strategic health security assets.
Strengthens U.S. vaccine sovereignty and biodefense independence amid great-power competition for medical countermeasure capabilities.
Generated by award_classification v2.1.0 via claude-haiku-4-5-20251001 on 2026-06-28. Cost: $0.019098.
- USAspending.gov — all awards for this UEI →
- SAM.gov entity registration →
- Award record ingested from usaspending. Source identifier CONT_AWD_75A50119C00071_7505_-NONE-_-NONE-.
The Buildout does not edit federal records. Any inaccuracy reflects the upstream source; it will update here when corrected there.